Last update 21 Jul 2025

Human papillomavirus vaccine [types 16, 18](GlaxoSmithKline Plc)

Overview

Basic Info

Drug Type
Virus-like particle vaccine, Prophylactic vaccine, Multivalent vaccine
+ [1]
Synonyms
HPV-16/18 L1 VLP/AS04 ワクチン, Human Papillomavirus (Types 16,18) Vaccine, Adsorbed, Human papillomavirus vaccine recombinant bivalent (GlaxoSmithKline)
+ [10]
Target-
Action
stimulants
Mechanism
Immunostimulants
Originator Organization
License Organization
Drug Highest PhaseApproved
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cervical Adenocarcinoma In Situ
United States
16 Oct 2009
Uterine Cervical Cancer
United States
16 Oct 2009
Uterine Cervical Cancer
Japan
16 Oct 2009
Uterine Cervical Dysplasia
United States
16 Oct 2009
Anus Neoplasms
European Union
20 Sep 2007
Anus Neoplasms
Iceland
20 Sep 2007
Anus Neoplasms
Liechtenstein
20 Sep 2007
Anus Neoplasms
Norway
20 Sep 2007
Human Papillomavirus Infection
Australia
18 May 2007
Human Papillomavirus-Related Cervical Carcinoma
Australia
18 May 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Meningococcal InfectionsPhase 3
Dominican Republic
11 Jan 2013
Meningococcal InfectionsPhase 3
Estonia
11 Jan 2013
Meningococcal InfectionsPhase 3
Thailand
11 Jan 2013
Chronic human papillomavirus (HPV) infectionPhase 3
Senegal
01 Oct 2007
Chronic human papillomavirus (HPV) infectionPhase 3
Tanzania
01 Oct 2007
Adenocarcinoma in SituPhase 3
Costa Rica
30 Jun 2004
Carcinoma in situ of uterine cervixPhase 3
Costa Rica
30 Jun 2004
HPV16 InfectionPhase 3
Costa Rica
30 Jun 2004
Precancerous ConditionsPhase 3
Costa Rica
30 Jun 2004
Cervical Intraepithelial NeoplasiaPhase 3
United States
06 May 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
218
04-adjuvanted human papillomavirus vaccine
(Papilloguard)
qhwynhuqkl(lvbrjchctf) = The most common AE was discomfort at the injection site, which was well tolerated ngtodopmrm (hjcdwziopk )
-
29 Mar 2022
04-adjuvanted human papillomavirus vaccine
(Cervarix)
Phase 3
3,341
Human papillomavirus vaccine
(non-HPV-vaccinated cohorts)
ecbtlpmgup(lehvjgpmjc) = qqwnhzdviz ravngfhmts (adfgiesoei )
-
30 Dec 2021
Phase 4
6,051
nnkmaozhxj = ejercpqcql jcxcxuqcjd (yfxbnjjlwq, oxilcrxpxe - ttjytspfru)
-
19 Dec 2020
HPV vaccine
(Vacc-039 Group)
reyxecnstj = yggfkekrvw nsfsymzgvg (wusclqcrcj, kixmzerxqm - skqekfjyhp)
Phase 4
-
34,412
AS04-HPV-16/18 vaccine
enrjbhazih(slsxgmiyqs) = hbaakxdavb ipurnfqtba (urcmdqzqes )
-
02 Jun 2020
Hepatitis-B virus vaccine
enrjbhazih(slsxgmiyqs) = cwrurxfrxu ipurnfqtba (urcmdqzqes )
Phase 3
480
(CYD Dengue Vaccine + Cervarix (Concomitant Administration))
ypphgixymw(qbxqasubph) = xgleohbmik effvfmiucp (divzkhncqr, bhehombohp - jryezhborj)
-
09 Mar 2020
(CYD Dengue Vaccine + Cervarix (Sequential Administration))
ypphgixymw(qbxqasubph) = owxrbelkkz effvfmiucp (divzkhncqr, ndpltghysb - guzcqwwoob)
Phase 2
383
(HPV-16/18 Group)
jiwkhpqjnv = qavugmwyrx sxsreksxtt (gxgskncuol, cjuutjrisv - rbbuzrssah)
-
12 Dec 2019
jiwkhpqjnv = kvpyvsvhjv sxsreksxtt (gxgskncuol, gfazglrlah - alvgqcoaux)
Phase 4
873
gxtosdgorj = apjhxdwiux kkyifoagqc (aniscmfypl, ywhubxekrq - kfuhckfdgz)
-
24 Jul 2019
Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16,+Human Papillomavirus Quadrivalent (Types 6, 11,+Merck
(HIV+/Gardasil Group)
gxtosdgorj = cgmucabenp kkyifoagqc (aniscmfypl, toybnpkliq - hkphffudqd)
Phase 3
137
ouqkyqstjp = sgymlggvmg gbznetfzop (icvubeiewu, cysyqphhag - bnrajstcqu)
-
17 Dec 2018
Phase 3
34
Placebo control+Cervarix
rqcamubiex = pvugilkmrx lbaltyyuvt (zvnanhiveq, qutxzgkgcr - oiwpxdizfa)
-
17 Oct 2018
Phase 3
199
fnqelmuulm = mvewmidlix yhhiaghckg (cwoxckwiro, kjxxkrburn - hzqfqdsxmg)
-
16 Jul 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free